Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Amortization of Deferred Charges: 2018-2022

Historic Amortization of Deferred Charges for Avadel Pharmaceuticals (AVDL) over the last 5 years, with Dec 2022 value amounting to $1.9 million.

  • Avadel Pharmaceuticals' Amortization of Deferred Charges rose 512.54% to $1.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $6.1 million, marking a year-over-year increase of 384.94%. This contributed to the annual value of $2.8 million for FY2023, which is 53.80% down from last year.
  • Avadel Pharmaceuticals' Amortization of Deferred Charges amounted to $1.9 million in Q4 2022, which was down 0.68% from $1.9 million recorded in Q3 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $1.9 million in Q3 2022 and a low of $311,000 during Q4 2021.
  • For the 3-year period, Avadel Pharmaceuticals' Amortization of Deferred Charges averaged around $1.2 million, with its median value being $1.6 million (2020).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first slumped by 81.59% in 2021, then spiked by 514.74% in 2022.
  • Avadel Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $1.4 million in 2018, then grew by 10.01% to $1.6 million in 2019, then rose by 7.51% to $1.7 million in 2020, then tumbled by 81.59% to $311,000 in 2021, then skyrocketed by 512.54% to $1.9 million in 2022.
  • Its Amortization of Deferred Charges stands at $1.9 million for Q4 2022, versus $1.9 million for Q3 2022 and $1.9 million for Q2 2022.